

Australian Standard™

Biological evaluation of medical devices

Part 4: Selection of tests for interactions with blood



This Australian Standard was prepared by Committee HE-012, Surgical Implants and Committee HE-009, Hypodermic Equipment—General Medical. It was approved on behalf of the Council of Standards Australia on 29 May 2003 and published on 30 June 2003.

The following are represented on Committee HE-012:

HE-012 and (HE-009):

Australian Chamber of Commerce and Industry (HE-009)
Australian College of Operating Room Nurses (HE-009)
Australian Dental Association
Australian Industry Group
Australian Orthopaedic Association
Australian Society for Biomaterials
Commonwealth Department of Health and Ageing (HE-009)
Department of Defence (Australia)
Medical Industry Association of Australia Inc (HE-009)
Neurological Society of Australasia
Royal Australasian College of Surgeons
Royal Perth Hospital
University of New South Wales
University of Sydney

HE-009 only:

Australian Infection Control Association
Australian Medical Association
Certification Bodies (Australia)
Department of Human Services (Victoria)
Federation of Sterilizing Research and Advisory Councils of Australia
Hunter Area Health Service
NSW Health Department
Queensland Health
Royal Australian College of General Practitioners
Royal College of Pathologists of Australasia
Royal Melbourne Hospital

Keeping Standards up-to-date

Standards are living documents which reflect progress in science, technology and systems. To maintain their currency, all Standards are periodically reviewed, and new editions are published. Between editions, amendments may be issued. Standards may also be withdrawn. It is important that readers assure themselves they are using a current Standard, which should include any amendments which may have been published since the Standard was purchased.

Detailed information about Standards can be found by visiting the Standards Australia web site at www.standards.com.au and looking up the relevant Standard in the on-line catalogue.

Alternatively, the printed Catalogue provides information current at 1 January each year, and the monthly magazine, *The Global Standard*, has a full listing of revisions and amendments published each month.

We also welcome suggestions for improvement in our Standards, and especially encourage readers to notify us immediately of any apparent inaccuracies or ambiguities. Contact us via email at mail@standards.com.au, or write to the Chief Executive, Standards Australia International Ltd, GPO Box 5420, Sydney, NSW 2001.

This Standard was issued in draft form for comment as DR 03172.

Australian Standard™

Biological evaluation of medical devices

Part 4: Selection of tests for interactions with blood

Originated as AS ISO 10993.4—2002.
Second edition 2003.

COPYRIGHT

© Standards Australia International

All rights are reserved. No part of this work may be reproduced or copied in any form or by any means, electronic or mechanical, including photocopying, without the written permission of the publisher.

Published by Standards Australia International Ltd
GPO Box 5420, Sydney, NSW 2001, Australia

ISBN 0 7337 5368 X

 **Documents**
Document Sharing Hub

PREFACE

This Standard was prepared by the Australian members of the Joint Standards Australia/ Standards New Zealand Committees HE-012, Surgical Implants and HE-009, Hypodermic Equipment—General Medical. After consultation with stakeholders in both countries, Standards Australia and Standards New Zealand decided to develop this Standard as an Australian, rather than an Australian/ New Zealand Standard.

This Standard is identical with and has been reproduced from ISO 10993-4:2002, *Biological evaluation of medical devices—Part 4: Selection of tests for interactions with blood*.

This second edition cancels and replaces the first edition (AS ISO 10993.4—2002), which has been technically revised.

The objective of this Standard is to specify general requirements for evaluating the interactions of medical devices with blood. This Standard describes a classification of medical and dental devices that are intended for use in contact with blood, based on the intended use and duration of contact, the fundamental principles governing the evaluation of the interaction of devices with blood, and the rationale for structured selection of tests according to specific categories, together with the principles and scientific basis of these tests.

The terms ‘normative’ and ‘informative’ are used to define the application of the annex to which they apply. A normative annex is an integral part of a standard, whereas an informative annex is only for information and guidance.

As this Standard is reproduced from an international Standard, the following applies:

- (a) Its number does not appear on each page of text and its identity is shown only on the cover and title page.
- (b) In the source text ‘this International Standard’ should read ‘this Australian Standard’.
- (c) A full point substitutes for a comma when referring to a decimal marker.

References to International Standards should be replaced by references to Australian or Australian/New Zealand Standards as follows:

<i>Reference to International Standard</i>	<i>Australian Standard</i>
ISO	AS ISO
10993 Biological evaluation of medical devices	10993 Biological evaluation of medical devices
10993-1 Part 1: Evaluation and testing	10993.1 Part 1: Evaluation and testing

AS ISO 10993, Biological evaluation of medical devices, consists of the following parts:

- Part 1: Evaluation and testing
- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
- Part 4: Selection of tests for interactions with blood (this Standard)
- Part 5: Tests for in vitro cytotoxicity
- Part 6: Tests for local effects after implantation
- Part 7: Ethylene oxide sterilization residuals
- Part 8: Selection and qualification of reference materials for biological tests
- Part 9: Framework for identification and quantification of potential degradation products
- Part 10: Tests for irritation and delayed-type hypersensitivity
- Part 11: Tests for systematic toxicity
- Part 12: Sample preparation and reference materials

Part 13: Identification and quantification of degradation products from polymeric medical devices

Part 14: Identification and quantification of degradation products from ceramics

Part 15: Identification and quantification of degradation products from metals and alloys

Part 16: Toxicokinetic study design for degradation products and leachables

CONTENTS

Introduction.....	v
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions	1
4 Abbreviated terms.....	2
5 Types of device in contact with blood (as categorized in ISO 10993-1).....	3
5.1 Non-contact devices	3
5.2 External communicating devices	3
5.3 Implant devices	4
6 Characterization of blood interactions	5
6.1 General requirements	5
6.2 Categories of tests and blood interactions	8
6.3 Types of test	11
Annex A (informative) Preclinical evaluation of cardiovascular devices and prostheses.....	13
Annex B (informative) Laboratory tests — Principles, scientific basis and interpretation.....	17
Annex C (informative) Evaluation of haemolytic properties of medical devices and their components	23
Bibliography.....	30

INTRODUCTION

The selection and design of test methods for the interactions of medical devices with blood should take into consideration device design, materials, clinical utility, usage environment and risk benefit. This level of specificity can only be covered in vertical standards.

The initial source for developing this part of ISO 10993 was the publication, *Guidelines for blood/material interactions*, Report of the National Heart, Lung, and Blood Institute [29]; chapters 9 and 10. This publication has since been revised [32].

AUSTRALIAN STANDARD

Biological evaluation of medical devices

Part 4: Selection of tests for interactions with blood

1 Scope

This part of ISO 10993 provides general requirements for evaluating the interactions of medical devices with blood.

It describes

- a) a classification of medical and dental devices that are intended for use in contact with blood, based on the intended use and duration of contact as defined in ISO 10993-1,
- b) the fundamental principles governing the evaluation of the interaction of devices with blood,
- c) the rationale for structured selection of tests according to specific categories, together with the principles and scientific basis of these tests.

Detailed requirements for testing cannot be specified because of limitations in the knowledge and precision of tests for interactions of devices with blood. This part of ISO 10993 describes biological evaluation in general terms and may not necessarily provide sufficient guidance for test methods for a specific device.

2 Normative references

The following normative documents contain provisions which, through reference in this text, constitute provisions of this part of ISO 10993. For dated references, subsequent amendments to, or revisions of, any of these publications do not apply. However, parties to agreements based on this part of ISO 10993 are encouraged to investigate the possibility of applying the most recent editions of the normative documents indicated below. For undated references, the latest edition of the normative document referred to applies. Members of ISO and IEC maintain registers of currently valid International Standards.

ISO 10993-1:1997, *Biological evaluation of medical devices — Part 1: Evaluation and testing*

ISO 10993-2:1992, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

3 Terms and definitions

For the purposes of this part of ISO 10993, the terms and definitions given in ISO 10993-1 and the following apply.

3.1

blood/device interaction

any interaction between blood or any component of blood and a device resulting in effects on the blood, or on any organ or tissue, or on the device

NOTE Such effects may or may not have clinically significant or undesirable consequences. Annex A contains further information on these interactions.

3.2**ex vivo**

term applied to a test system that shunts blood directly from a human subject or test animal into a test chamber located outside the body

NOTE If using an animal model, the blood may be shunted directly back into the animal (recirculating) or collected into test tubes for evaluation (single pass).

3.3**thrombosis**

in vivo phenomenon resulting in the partial or complete occlusion of a vessel or device by a thrombus

NOTE 1 Characterization of thrombosis includes *ex vivo* and *in vivo* methods, in either animals or the clinical setting.

NOTE 2 A thrombus is composed of a mixture of red cells, aggregated platelets, fibrin and other cellular elements.

3.4**coagulation**

phenomenon that results from activation of the clotting factor cascade

NOTE Factors of the coagulation cascade and fibrinolytic systems can be measured following exposure to devices either *in vitro* or *in vivo*.

3.5**platelet**

anuclear, cellular body that is present in the circulation which adheres to surfaces and aggregates to form a hemostatic plug to minimize bleeding

NOTE Platelet testing includes quantification of platelet numbers as well as analysis of their structure and function. The testing can include analysis of platelet factors, or components on the platelet surface which are released from platelets or adherent to the device surface.

3.6**haematology**

study of blood, including quantification of cellular and plasma components of the blood

3.7**complement system**

part of the innate immune system, consisting of several plasma proteins, including enzymes and cellular receptors

NOTE Effector molecules produced from complement components are involved in inflammation, phagocytosis and cell lysis.

4 Abbreviated terms

Bb	product of alternative pathway complement activation
β-TG	beta-thromboglobulin
C4d	product of classical pathway complement activation
C3a, C5a	(active) complement split products from C3 and C5
CD62L	L-selectin
CH-50	50% total haemolytic complement
CT	computerized tomography
D-Dimer	specific fibrin degradation products (F XIII cross-linked fibrin)
ECMO	extracorporeal membrane oxygenator

ELISA	enzyme/linked immunosorbent assay
EM	electron microscopy
FDP	fibrin/fibrinogen degradation products
FPA	fibrinopeptide A
F ₁₊₂	prothrombin activation fragment 1 + 2
iC3b	product of central C complement activation
IVC	inferior vena cava
MRI	magnetic resonance imaging
PAC-1	monoclonal antibody which recognizes the activated form of platelet surface glycoprotein IIb/IIIa
PET	positron emission tomography
PF-4	platelet factor 4
PRP	platelet-rich plasma
PT	prothrombin time
PTT	partial thromboplastin time
P-selectin	receptor exposed during either platelet or endothelial cell release reaction
RIA	radioimmunoassay
S-12	monoclonal antibody, which recognizes the alpha-granule membrane component P-selectin exposed during the platelet release reaction
SC5b-9	product of terminal pathway complement activation
TAT	thrombin-antithrombin complex
TCC	terminal complement complex
TT	thrombin time
VWF	von Willebrand factor

5 Types of device in contact with blood (as categorized in ISO 10993-1)

5.1 Non-contact devices

An *in vitro* diagnostic device is an example of a non-contact device.

5.2 External communicating devices

These are devices that contact the circulating blood and serve as a conduit into the vascular system. Examples include but are not limited to those in ISO 10993-1.

- a) External communicating devices that serve as an indirect blood path include but are not limited to
- cannulae,
 - extension sets,
 - blood collection devices,
 - devices for the storage and administration of blood and blood products (e.g. tubing, needles and bags),
 - cell savers.

b) External communicating devices in contact with circulating blood include but are not limited to

- atherectomy devices,
- blood monitors,
- catheters,
- guidewires,
- intravascular endoscopes,
- intravascular ultrasound,
- intravascular laser systems,
- retrograde coronary perfusion catheters,
- cardiopulmonary bypass circuitry,
- extracorporeal membrane oxygenators,
- haemodialysis/haemofiltration equipment,
- donor and therapeutic apheresis equipment,
- devices for absorption of specific substances from blood,
- interventional cardiology and vascular devices,
- percutaneous circulatory support systems.

5.3 Implant devices

Implant devices are placed largely or entirely within the vascular system. Examples include but are not limited to

- annuloplasty rings,
- mechanical or tissue heart valves,
- prosthetic or tissue vascular grafts,
- circulatory support devices (ventricular-assist devices, artificial hearts, intra-aortic balloon pumps),
- inferior vena cava filters,
- embolization devices,
- endovascular grafts,
- implantable defibrillators and cardioverters,
- stents,
- arteriovenous shunts,
- blood monitors,

- internal drug delivery catheters,
- pacemaker leads,
- intravascular membrane oxygenators (artificial lungs),
- leukocyte-removal filters.

6 Characterization of blood interactions

6.1 General requirements

6.1.1 Figure 1 illustrates a decision tree that can be used to determine whether testing for interaction with blood is necessary.

Blood interactions can be classified into five categories based on the primary process or system being measured.

Tables 1 and 2 list examples of devices which contact circulating blood and the categories of testing appropriate to the device.

NOTE Since this is a horizontal International Standard, good rationales can be developed to justify the choice of category based on the device being characterized. Thrombosis testing is frequently the preferred method for device characterization. In many cases, rationales can be used to substitute some combination of coagulation, platelets, haematology and complement system testing for thrombosis testing.

For medical devices where a specific International Standard (vertical standard) exists, the biological evaluation requirements and test methods set forth in that vertical standard shall take precedence over the general requirements suggested in this part of ISO 10993.

6.1.2 Where possible, tests shall use an appropriate model or system which simulates the geometry and conditions of contact of the device with blood during clinical applications, including duration of contact, temperature, sterile condition and flow conditions. For devices of defined geometry, the ratio of test parameter (concentration per unit volume) to exposed surface area (cm²) shall be evaluated.

Only blood-contacting parts should be tested. The selected test methods and parameters should be in accordance with the current state of the art.

6.1.3 Controls shall be used unless their omission can be justified. Where possible, testing should include a relevant device already in clinical use or a well-characterized reference material [7].

Reference materials used should include negative and positive controls. All materials and devices tested shall meet all quality control and quality assurance specifications of the manufacturer and test laboratory. All materials and devices tested shall be identified as to source, manufacturer, grade and type.

6.1.4 Testing of materials which are candidates for components of a device may be conducted for screening purposes. However, such preliminary tests do not serve as a substitute for the requirement that the complete device or device component be tested under conditions which simulate or exaggerate clinical application.

6.1.5 Tests which do not simulate the conditions of a device during use may not predict accurately the nature of the blood/device interactions which can occur during clinical applications. For example, some short-term *in vitro* or *ex vivo* tests are poor predictors of long-term *in vivo* blood/device interactions [25], [26].

6.1.6 It follows from the above that devices whose intended use is *ex vivo* (external communication) should be tested *ex vivo* and devices whose intended use is *in vivo* (implants) should be tested *in vivo* in an animal model simulating as closely as possible conditions of clinical use.




Figure 1 — Decision tree to determine whether testing for interaction with blood is necessary